Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ONCT 
Oncternal Therapeutics Inc (ONCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ONCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.57% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta 1.33 | 52 Weeks Range 0.53 - 9.88 | Updated Date 04/1/2025 |
52 Weeks Range 0.53 - 9.88 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.69 |
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1757.29% |
Management Effectiveness
Return on Assets (TTM) -76.45% | Return on Equity (TTM) -149.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12828451 | Price to Sales(TTM) 0.72 |
Enterprise Value -12828451 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.85 | Enterprise Value to EBITDA 0.15 | Shares Outstanding 2959640 | Shares Floating 2706683 |
Shares Outstanding 2959640 | Shares Floating 2706683 | ||
Percent Insiders 9.23 | Percent Institutions 12.07 |
Analyst Ratings
Rating 3 | Target Price 1.93 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Oncternal Therapeutics Inc
Company Overview
History and Background
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2012. It focuses on developing novel therapies for cancers with unmet medical needs. The company has advanced multiple programs into clinical development.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing therapies for various types of cancer, primarily through clinical trials and research activities.
Leadership and Structure
James Breitmeyer, MD, PhD is the CEO. The company has a typical structure for a biotech with research, clinical development, and business operations departments.
Top Products and Market Share
Key Offerings
- Cirmtuzumab: An anti-ROR1 monoclonal antibody being evaluated in clinical trials for various cancers. Market share is currently 0 as it is still in development. Competitors include companies developing ROR1-targeting therapies, such as ADC Therapeutics and Bristol Myers Squibb (BMS).
- TK216: An investigational Ets-family transcription factor inhibitor for Ewing sarcoma. Market share is currently 0 as it is still in development. Competitors include companies developing therapies for Ewing sarcoma, such as Y-mAbs Therapeutics.
Market Dynamics
Industry Overview
The oncology market is large and competitive, with significant unmet needs across various cancer types. There's increasing demand for targeted therapies and immunotherapies.
Positioning
Oncternal is positioning itself as a developer of targeted therapies with novel mechanisms of action. Its competitive advantage lies in its focus on ROR1 and Ets-family transcription factors.
Total Addressable Market (TAM)
The TAM for oncology therapies is estimated to be hundreds of billions of dollars. Oncternal is targeting niche segments within this market, such as ROR1-positive cancers and Ewing sarcoma.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (ROR1, Ets)
- Clinical-stage pipeline
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No approved products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ADCT
- BMY
- YMAB
Competitive Landscape
Oncternal faces significant competition from larger pharmaceutical companies with more resources. Its advantage lies in its novel therapeutic targets and focus on specific cancer subtypes. All values are 0 as drugs are still in trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and clinical trial advancement.
Future Projections: Future growth depends on successful clinical trials and potential FDA approval of its drug candidates. Analyst estimates will vary based on perceived probability of success.
Recent Initiatives: Recent initiatives include advancing clinical trials and seeking partnerships.
Summary
Oncternal Therapeutics is a clinical-stage biotech company with a promising pipeline of novel cancer therapies. Its strength lies in its unique therapeutic targets, but it faces challenges due to limited resources and the inherent risks of clinical development. Successful clinical trial outcomes and strategic partnerships will be critical for its future success.
Similar Companies
ADCT
ADC Therapeutics SA
ADCT
ADC Therapeutics SA
YMAB
Y mAbs Therapeutics
YMAB
Y mAbs Therapeutics
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncternal Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-02-03 | President, CEO & Director Dr. James B. Breitmeyer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.oncternal.com |
Full time employees 27 | Website https://www.oncternal.com | ||
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.